Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 3/2009

01-02-2009 | Erratum

Identification, characterization and potent antitumor activity of ECO-4601, a novel peripheral benzodiazepine receptor ligand

Authors: Henriette Gourdeau, James B. McAlpine, Maxime Ranger, Bryan Simard, Francois Berger, Francis Beaudry, Chris M. Farnet, Pierre Falardeau

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2009

Login to get access

Excerpt

In this article the authors list has been revised to the following: Henriette Gourdeau, James B. McAlpine, Maxime Ranger, Bryan Simard, Francois Berger, Francis Beaudry, Chris M. Farnet and Pierre Falardeau. …
Metadata
Title
Identification, characterization and potent antitumor activity of ECO-4601, a novel peripheral benzodiazepine receptor ligand
Authors
Henriette Gourdeau
James B. McAlpine
Maxime Ranger
Bryan Simard
Francois Berger
Francis Beaudry
Chris M. Farnet
Pierre Falardeau
Publication date
01-02-2009
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 3/2009
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-008-0848-x

Other articles of this Issue 3/2009

Cancer Chemotherapy and Pharmacology 3/2009 Go to the issue

Erratum

Detection of complete response to imatinib mesylate (Glivec®/Gleevec®) with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma

Original Article

Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine

Short Communication

Carbamazepine induces bioactivation of cyclophosphamide and thiotepa

Original Article

Combination therapy with docetaxel and low dose of cisplatin in elderly patients with advanced non-small cell lung cancer: multicenter phase II study

Original Article

A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state

Letter to the Editor

Pharmacokinetic profile of imatinib mesylate and N-desmethyl-imatinib (CGP 74588) in children with newly diagnosed Ph+ acute leukemias
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits